Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate plus dexmedetomidine sedation dosing for hallux valgus surgery
ChiCTR2400089989Phase 4Not yet recruiting
- Sponsor
- Nanhua Hospital affiliated to Nanhua University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam and dexmedetomidine in bunion deformity (HAV), sponsored by Nanhua Hospital affiliated to Nanhua University. Primary endpoint: Successful sedation. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
bunion deformity (HAV)
Beyond the preview
Go deeper on ChiCTR2400089989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089989.